perceptive™

Overcoming Complexities in Parkinson's Disease Research



End-to-End Imaging Expertise

Perceptive delivers a fully integrated, end-to-end imaging solution for Parkinson's disease (PD), supporting sponsors from preclinical discovery through translational refinement and scalable late-phase global trials with a unified operational and scientific framework.

Our proprietary, PPMI-informed multimodal pipelines and AI-driven analytic workflows deliver consistency, sensitivity, and regulatory-ready data across every stage of PD therapeutic development.

Unmatched CNS & Neuro-degenerative Leadership

- 30 years of CNS radiotracer and neuroimaging innovation
- 750+ CNS clinical trials supported, with 140+ PD trials
- 800+ preclinical neurodegenerative studies supported

Proven Imaging Science & Analytics

- Established visual read paradigms and advanced PD-specific quantitative imaging analysis
- Deep expertise in PET, SPECT, MRI, and advanced neuroimaging techniques

Global Scale & Operational Excellence

- 2,000+ qualified PET/SPECT/MRI imaging centers
- Strong imaging core lab footprint and site support across APAC
- 80K+ subjects imaged across PD and Alzheimer's studies

Meet Our Parkinson's Imaging Leadership Team



Rohit Sood, MD, PhD
VP, Scientific and



David Cash, PhD
Sr. Medical Director



Elif Sikoglu, PhD
Sr. Scientific Director



Sam Lockhart, PhD
Sr. Scientific Director



Lisa Wells
VP, Translational Pharmacology

Parkinson's Imaging Services

Industry-leading tools for Neuro PET, SPECT and MRI analysis including:

PRECLINICAL	
BIODISTRIBUTION	**NEUROINFLAMMATION**
Target engagement & Occupancy studies	Biological therapeutics
Neuro pharmacodynamics	Pharmacokinetics
Neurotransmitter	Neuromodulator analysis
	Neurogenetics

Perceptive supports a range of first-in-human, pre-proof of concept clinical imaging studies spanning Phases I-IIa.

EARLY PHASE	
Radioligand dosimetry	Biological therapeutics
Quantitative drug brain distribution	Pharmacokinetics
Test-retest reliability, Invasive and	Pharmacokinetics
Target engagement	Tissue microstructure
Drug concentration – target occupancy	Tissue susceptibility
Pharmacodynamic responses	Pharmacodynamic responses

Target Characterization, including:

- 11C-PHNO - D2 dopamine receptor
- 18F-AV133 - VMAT2 (vesicular monoamine transporter)
- 11C-UCB-J Sv2A tracer
- 18F-BCPP-EF Mictochondrial complex 1 (MC1) tracer
- 11C-PHNO - D2 dopamine receptor

LATE PHASE
Visual neuroradiology reads for eligibility and safety (based on DaT, PET or MR Imaging)
Validated analysis pipelines
SUVr, centiloid, extent analysis
Advanced MRI analysis
Biomathematical modeling tools
Complete project support: study design to data management
Experienced neuroradiologist pool
Expertise in quantitative analysis for monitoring therapeutic effects
Novel tracer read and analysis approaches



Quantitative Image Analysis Pipelines

Perceptive has developed and is continually enhancing and operationalizing analysis pipelines based on the Parkinson's Progression Markers Initiative (PPMI), including both PET and MR imaging workflows. These tools are optimized for disease progression modeling and understanding therapeutic response and have been validated across multicenter studies.

Perceptive's DAT SPECT and AV-133 pipelines provide fast, standardized, and compliant neuroimaging analysis, using robust correction, precise normalization, and automated regional quantification to deliver high-quality, reproducible biomarker data for clinical trials.

©2026 Perceptive

Contact
hello@perceptive.com

perceptive